<div>
  <ul>
    <li>
      <p>
        Israeli AI drug discovery company Quris-AI expanded the existing collaboration with pharma giant Merck KGaA for drug toxicity prediction.
      </p>
    </li>
    <li>
      <p>
        The partnership will leverage Quris-AI's platform to identify liver toxicity risks in drug candidates. Merck KGaA has the option to obtain an exclusive license to a specific disease domain, and if exercised, Quris-AI may receive an undisclosed amount. The collaboration aims to reduce the reliance on animal testing and improve the efficiency of drug development and testing programs.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.quris.ai/merckkgaa-quris-ai-expand-collaboration">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.fiercebiotech.com/biotech/merck-kgaa-goes-again-ai-expanding-quris-toxicity-prediction-pact-days-after-inking-2-deals">
      Fierce Biotech
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

Israeli AI drug discovery company Quris-AI has extended its partnership with pharma company Merck KGaA to focus on identifying liver toxicity risks in drug candidates. Quris-AI's platform will be utilized to predict drug toxicity, with Merck KGaA having the option to obtain an exclusive license for a specific disease area. In exchange, Quris-AI may receive an undisclosed amount. The collaboration aims to reduce the need for animal testing and enhance the effectiveness of drug development and testing processes.

All Updates

Quris-AI and Merck expand existing partnership for drug toxicity prediction

Quris raises an additional USD 9 million in seed funding

Quris partners with Merck to assess clinical safety prediction solution

Quris raises USD 19 million in seed funding